The serum concentration of Topotecan can be increased when it is combined with Buprenorphine. The therapeutic efficacy of Tecemotide can be decreased when used in combination with Glimepiride. The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Ethinyl Estradiol. The serum concentration of Lisinopril can be decreased when it is combined with Lanthanum carbonate. The metabolism of Phenformin can be decreased when combined with Bupropion. The metabolism of Irbesartan can be increased when combined with Aprepitant. The risk or severity of adverse effects can be increased when Etidocaine is combined with Trimipramine. The metabolism of Selegiline can be decreased when combined with Valsartan. Edrophonium may increase the bradycardic activities of Atenolol. The risk or severity of adverse effects can be increased when PTC299 is combined with Carbaspirin calcium. The serum concentration of Perhexiline can be decreased when it is combined with Efavirenz. The metabolism of Famciclovir can be decreased when combined with Delavirdine. The risk or severity of adverse effects can be increased when Zileuton is combined with Naproxen. The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Nefazodone. Cyclopenthiazide may increase the hypercalcemic activities of Calcidiol. The risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Phenylpropanolamine. The risk or severity of adverse effects can be increased when Tacrolimus is combined with Triamcinolone. The serum concentration of Dabrafenib can be decreased when it is combined with Aluminum hydroxide. The risk or severity of adverse effects can be increased when Topiramate is combined with Cyclizine. The metabolism of Fulvestrant can be decreased when combined with Sulfisoxazole. The risk or severity of adverse effects can be increased when Simeprevir is combined with Oxycodone. Nandrolone may increase the hypoglycemic activities of Sulfadiazine. Mivacurium may increase the adverse neuromuscular activities of Betamethasone. Nalidixic Acid may increase the hypoglycemic activities of Glimepiride. The serum concentration of Ethyl biscoumacetate can be decreased when it is combined with Griseofulvin. Naftifine may decrease the excretion rate of Gentamicin which could result in a higher serum level. Metocurine may increase the arrhythmogenic activities of Proscillaridin. The metabolism of Ipratropium bromide can be decreased when combined with Thioridazine. The metabolism of Sulfisoxazole can be increased when combined with Primidone. The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Ketoprofen. The metabolism of Sulfadiazine can be decreased when combined with Topiroxostat. The metabolism of Felodipine can be decreased when combined with Nefazodone. The risk or severity of adverse effects can be increased when Methohexital is combined with Ethyl carbamate. The metabolism of Paritaprevir can be decreased when combined with Diltiazem. The metabolism of Metronidazole can be decreased when combined with Manidipine. The risk or severity of adverse effects can be increased when Octamoxin is combined with Salmeterol. The risk or severity of adverse effects can be increased when Nimesulide is combined with Ibuproxam. Cryptenamine may increase the hypotensive activities of Chlorothiazide. Benzydamine may decrease the excretion rate of Plicamycin which could result in a higher serum level. The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Equilin. The serum concentration of Levothyroxine can be increased when it is combined with Simeprevir. Phenylbutazone may decrease the antihypertensive activities of Propranolol. Pentoxifylline may increase the hypotensive activities of Rescinnamine. The serum concentration of Lorcaserin can be increased when it is combined with Cobicistat. The therapeutic efficacy of Latanoprost can be decreased when used in combination with Benzydamine. Isoxsuprine may increase the orthostatic hypotensive activities of Levodopa. Safrazine may increase the hypotensive activities of Felodipine. Ropinirole may increase the atrioventricular blocking (AV block) activities of Pindolol. Phenelzine may increase the hypotensive activities of Clonidine. The therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Citrate. Isoflurane may increase the orthostatic hypotensive activities of Levodopa. Telmisartan may increase the hypotensive activities of Bupranolol. The metabolism of Naproxen can be increased when combined with Secobarbital. The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Trichlormethiazide. The metabolism of Antipyrine can be decreased when combined with Methadone. The risk or severity of adverse effects can be increased when Prasterone is combined with Rindopepimut. Ibuprofen may increase the anticoagulant activities of Warfarin. Flunisolide may increase the hypokalemic activities of Bendroflumethiazide. The risk or severity of adverse effects can be increased when Amobarbital is combined with Ketazolam. The bioavailability of Prednisone can be decreased when combined with Magnesium oxide. The risk or severity of adverse effects can be increased when Bupivacaine is combined with Bendroflumethiazide. Cyclosporine may increase the neuromuscular blocking activities of Cisatracurium besylate. The risk or severity of adverse effects can be increased when Oxybutynin is combined with Atorvastatin. The risk or severity of adverse effects can be increased when Bumetanide is combined with Hydrochlorothiazide. Nimesulide may increase the anticoagulant activities of Eplivanserin. The metabolism of Prasugrel can be decreased when combined with Sulfisoxazole. Salicylamide may decrease the excretion rate of Streptomycin which could result in a higher serum level. The risk or severity of adverse effects can be increased when Mometasone is combined with G17DT. The serum concentration of Thioproperazine can be increased when it is combined with Trimethoprim. The serum concentration of Acetylsalicylic acid can be increased when it is combined with Ranolazine. The therapeutic efficacy of Clarithromycin can be decreased when used in combination with Saxagliptin. The serum concentration of Metipranolol can be increased when it is combined with Milnacipran. The risk or severity of adverse effects can be increased when Nitrendipine is combined with Mannitol. The therapeutic efficacy of INGN 201 can be decreased when used in combination with Fluorouracil. Diclofenac may decrease the excretion rate of Ribostamycin which could result in a higher serum level. Paliperidone may increase the atrioventricular blocking (AV block) activities of Bopindolol. The risk or severity of adverse effects can be increased when Candesartan is combined with Ketorolac. The risk or severity of adverse effects can be increased when Enalapril is combined with Nafamostat. The metabolism of Valsartan can be decreased when combined with Efavirenz. The risk or severity of adverse effects can be increased when Bortezomib is combined with Reserpine. The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Losartan. Chlorothiazide may increase the hypotensive activities of Cyclopenthiazide. The serum concentration of Dienestrol can be decreased when it is combined with Ixazomib. The risk or severity of adverse effects can be increased when Metoprolol is combined with Bendroflumethiazide. Spironolactone may decrease the vasoconstricting activities of Brimonidine. The risk or severity of adverse effects can be increased when Fentanyl is combined with Barbital. The risk or severity of adverse effects can be increased when Methohexital is combined with Levocabastine. Mebanazine may increase the hypotensive activities of Nadolol. Dihydroergotamine may increase the hypertensive activities of Olodaterol. The risk or severity of adverse effects can be increased when Hexobarbital is combined with Clidinium. The serum concentration of Amodiaquine can be increased when it is combined with Troglitazone. The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dapagliflozin. Niflumic Acid may decrease the antihypertensive activities of Bucindolol. The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Ketobemidone. The risk or severity of adverse effects can be increased when Valproic Acid is combined with Cyclizine. Flurbiprofen may decrease the excretion rate of Neomycin which could result in a higher serum level. The risk or severity of adverse effects can be increased when Nitroxoline is combined with Lercanidipine. The metabolism of Glipizide can be decreased when combined with Sulfisoxazole. The metabolism of Ethanol can be increased when combined with Rifabutin. Omeprazole can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy. The risk or severity of adverse effects can be increased when Masoprocol is combined with Adapalene. The serum concentration of Imatinib can be increased when it is combined with Dihydroergotamine. Methylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine. The metabolism of Fluoxetine can be decreased when combined with Sulfadiazine. Cilazapril may increase the hypotensive activities of Ambrisentan. The serum concentration of Pregnenolone can be increased when it is combined with Darunavir. The risk or severity of adverse effects can be increased when Tetracaine is combined with Methsuximide. The risk or severity of adverse effects can be increased when Bromocriptine is combined with Lercanidipine. The risk or severity of adverse effects can be increased when Methaqualone is combined with Chlorzoxazone. The metabolism of Brinzolamide can be decreased when combined with Verapamil. The therapeutic efficacy of Alprostadil can be decreased when used in combination with Semapimod. Sucralfate can cause a decrease in the absorption of Flucytosine resulting in a reduced serum concentration and potentially a decrease in efficacy. The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Levonorgestrel. The risk or severity of adverse effects can be increased when Oxycodone is combined with Baclofen. The risk or severity of adverse effects can be increased when Anidulafungin is combined with Xylometazoline. Hydrocortisone may increase the hypokalemic activities of Methyclothiazide. The risk or severity of adverse effects can be increased when Milrinone is combined with Carbaspirin calcium. Triptorelin may increase the QTc-prolonging activities of Erythromycin. The serum concentration of Cerivastatin can be increased when it is combined with Ivacaftor. The risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Hepatitis A Vaccine. Droxidopa may increase the hypokalemic activities of Metolazone. The serum concentration of Chlorothiazide can be increased when it is combined with Cyclopentolate. The risk or severity of adverse effects can be increased when Methscopolamine is combined with Dezocine. The serum concentration of Prucalopride can be increased when it is combined with Ivacaftor. The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with E-6201. The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Papaverine. Flurandrenolide may increase the hyperglycemic activities of Ceritinib. The risk or severity of adverse effects can be increased when Metolazone is combined with Quinapril. The serum concentration of Bendroflumethiazide can be increased when it is combined with Desloratadine. The metabolism of Epinastine can be decreased when combined with Artemether.